Avid Bioservices Inc (CDMO)

[nuke661]

MM,

This is my quick review of the liver data. First, here is a link to the sharp trial data:

sharp trial data

Using the slides from cheynew's post:

Yopp Slides

Comparing class of patients:
Sharp only had Child-Pugh of A, The Yopp trial had A and B7
The Sharp required platelet counts of >60 x 10^9/l (60 x10^6/ml (mm^3)). Yopp trial allowed platelet counts as low as 70 x 10^4 mm^3 (ml)). These are the only things I can discern as differences with the handicap on the Yopp trial compared to the Sharp trial. To what degree this represents the medical community will have to weigh in.

The one thing that sticks out to me to be in the Yopp trial's favor is that the Sharp trial had 602 with none alive after 17 months. The Yopp trial had a lot less (38 patients) but 3 are still alive after (what I interpret as greater than) 18 months when looking at the curves on page 4 for number of patients at risk and the table on page 15. Again it looks like there may be distinct advantage to having Bavi in the mix. Anyone, please feel free to weigh in on this. Much appreciated if you do.